TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Vekić, Jelena
AU  - Koulouris, Spyridon
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Rini, Giovam Battista
AU  - Sakellariou, Dimitrios
AU  - Pastromas, Socrates
AU  - Mikhailidis, Dimitri P.
AU  - Manolis, Antonis S.
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1398
AB  - Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Angiology
T1  - Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
VL  - 61
IS  - 6
SP  - 584
EP  - 590
DO  - 10.1177/0003319710366431
ER  - 

@article{
author = "Rizzo, Manfredi and Vekić, Jelena and Koulouris, Spyridon and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Rini, Giovam Battista and Sakellariou, Dimitrios and Pastromas, Socrates and Mikhailidis, Dimitri P. and Manolis, Antonis S.",
year = "2010",
abstract = "Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Angiology",
title = "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes",
volume = "61",
number = "6",
pages = "584-590",
doi = "10.1177/0003319710366431"
}

Rizzo, M., Vekić, J., Koulouris, S., Zeljković, A., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V., Rini, G. B., Sakellariou, D., Pastromas, S., Mikhailidis, D. P.,& Manolis, A. S.. (2010). Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology
Sage Publications Inc, Thousand Oaks., 61(6), 584-590.
https://doi.org/10.1177/0003319710366431

Rizzo M, Vekić J, Koulouris S, Zeljković A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS. Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. in Angiology. 2010;61(6):584-590.
doi:10.1177/0003319710366431 .

Rizzo, Manfredi, Vekić, Jelena, Koulouris, Spyridon, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Rini, Giovam Battista, Sakellariou, Dimitrios, Pastromas, Socrates, Mikhailidis, Dimitri P., Manolis, Antonis S., "Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes" in Angiology, 61, no. 6 (2010):584-590,
https://doi.org/10.1177/0003319710366431 . .

TY  - JOUR
AU  - Rizzo, Manfredi
AU  - Kotur-Stevuljević, Jelena
AU  - Berneis, Kaspar
AU  - Spinas, Giatgen
AU  - Rini, Giovam Battista
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Vekić, Jelena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1228
AB  - Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required to explore the potential synergistic impact of markers of oxidative stress and atherogenic dyslipidemia, particularly small dense LDL, on cardiovascular risk. (Translational Research 2009; 153:217-223)
PB  - Elsevier Science Inc, New York
T2  - Transplant International
T1  - Atherogenic dyslipidemia and oxidative stress: a new look
VL  - 153
IS  - 5
SP  - 217
EP  - 223
DO  - 10.1016/j.trsl.2009.01.008
ER  - 

@article{
author = "Rizzo, Manfredi and Kotur-Stevuljević, Jelena and Berneis, Kaspar and Spinas, Giatgen and Rini, Giovam Battista and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Vekić, Jelena",
year = "2009",
abstract = "Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required to explore the potential synergistic impact of markers of oxidative stress and atherogenic dyslipidemia, particularly small dense LDL, on cardiovascular risk. (Translational Research 2009; 153:217-223)",
publisher = "Elsevier Science Inc, New York",
journal = "Transplant International",
title = "Atherogenic dyslipidemia and oxidative stress: a new look",
volume = "153",
number = "5",
pages = "217-223",
doi = "10.1016/j.trsl.2009.01.008"
}

Rizzo, M., Kotur-Stevuljević, J., Berneis, K., Spinas, G., Rini, G. B., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Vekić, J.. (2009). Atherogenic dyslipidemia and oxidative stress: a new look. in Transplant International
Elsevier Science Inc, New York., 153(5), 217-223.
https://doi.org/10.1016/j.trsl.2009.01.008

Rizzo M, Kotur-Stevuljević J, Berneis K, Spinas G, Rini GB, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Vekić J. Atherogenic dyslipidemia and oxidative stress: a new look. in Transplant International. 2009;153(5):217-223.
doi:10.1016/j.trsl.2009.01.008 .

Rizzo, Manfredi, Kotur-Stevuljević, Jelena, Berneis, Kaspar, Spinas, Giatgen, Rini, Giovam Battista, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Vekić, Jelena, "Atherogenic dyslipidemia and oxidative stress: a new look" in Transplant International, 153, no. 5 (2009):217-223,
https://doi.org/10.1016/j.trsl.2009.01.008 . .